InMed Pharmaceuticals Inc. / Mentari Therapeutics, Inc.
2026 · Reverse Merger · $290M · Pending
Announcement Sentiment
40
Skeptical
InMed Pharmaceuticals entered an all-stock definitive merger agreement with Mentari Therapeutics, a private migraine biotech. Combined company will operate as Mentari Therapeutics with concurrent oversubscribed $290 million private placement led by Fairmount with Commodore, Deep Track, Janus Henderson, a16z Bio + Health, Venrock, Wellington, TCGX, Blackstone and others. First-in-human filings expected mid-2026 (MT-001) and Q1 2027 (MT-002).
Key facts
AnnouncedMay 19, 2026
Deal value$290M
Deal typeReverse Merger
Therapeutic areamigraine prevention
Indicationsmigraine prevention
Key assetsMT-001 (anti-PACAP) and MT-002 (anti-CGRP x PACAP bispecific)
Mechanismanti-PACAP monoclonal antibody (MT-001); anti-CGRP x PACAP bispecific (MT-002)